Aelis Farma Announces the Successful Start of the Recruitment of the Phase 2B Clinical Trial with AEF0217 for the Treatment of Behavioral and Cognitive Impairments of People with Down Syndrome (Trisomy 21)

Why It Matters

The trial could deliver the first approved drug to address cognitive deficits in Down syndrome, opening a sizable unmet‑need market and validating the CB1‑SSi therapeutic class.

Key Takeaways

• Phase 2B trial enrolls 188 Down syndrome participants
• Multi‑country sites in France, Italy, Spain begin recruitment
• AEF0217 is first‑in‑class CB1‑SSi targeting receptor hyperactivity
• Prior Phase 1/2 showed safety and adaptive‑behavior gains
• Results anticipated late 2027; cash runway extends to 2028

Pulse Analysis

Down syndrome remains one of the few neurodevelopmental disorders without an approved pharmacologic therapy for its core cognitive and adaptive challenges. Researchers have linked the condition to hyperactivity of the CB1 receptor within the endocannabinoid system, a pathway that influences learning, memory, and synaptic plasticity. AEF0217, Aelis Farma’s novel CB1‑signalling‑specific inhibitor, is engineered to dampen disease‑related receptor activity while sparing normal physiological functions, thereby sidestepping the adverse effects that halted earlier CB1 antagonists. This mechanistic precision positions the compound as a potentially transformative option for a population that currently relies on educational and behavioral interventions alone.

The Phase 2B trial, designated AEF0217‑201, expands on promising Phase 1/2 findings by enrolling 188 participants across ten expert sites in France, Italy and Spain. The double‑blind, placebo‑controlled design randomises patients 1:1:1:1 to daily doses of 0.1 mg, 0.2 mg, 0.6 mg, or placebo for a six‑month treatment period, followed by an eight‑week safety follow‑up. Primary efficacy will be assessed via the Vineland Adaptive Behaviour Scales‑3, while secondary endpoints capture cognition, quality of life, and sleep efficiency. An interim safety analysis after 40 participants complete 12 weeks underscores the study’s rigorous monitoring, and the broader enrolment aims to confirm both the magnitude and durability of the adaptive‑behavior gains observed earlier.

If successful, AEF0217 could become the first disease‑modifying therapy for Down syndrome, unlocking a market estimated at several hundred million euros globally. Beyond the immediate therapeutic impact, the trial validates the CB1‑SSi platform, paving the way for Aelis Farma to explore similar approaches in other neurodevelopmental and metabolic disorders. The company’s cash runway through Q1 2028 provides financial stability to advance the trial and potentially accelerate subsequent development programs, making the upcoming data a focal point for investors and clinicians alike.